Net profit for the three months ended June 30 was RM13.7 million, up 37%, the company said it filed with the Malaysian Stock Exchange today. Pharmaniaga announced a second interim dividend of 1.5 cents per share.
The company provided the government with 12.4 million doses of the vaccine, with the last batch shipped on July 21. Last week, Pharmamaniaga announced that it had secured an additional 6 million orders from the government.
“The Group has submitted to the NPRA for approval of a vaccine for use in Malaysian adolescents, which will create a demand for 6 million doses of the vaccine,” he said.
Recently, the Sinovac vaccine was approved in Indonesia and China for adolescents aged 12 to 17.
In addition, due to the increasing prevalence of Covid-19 in children, six countries are currently evaluating the use of Sinovac in adolescence.
Meanwhile, a new study in China suggests that a third dose of the Sinovac vaccine, given more than 6 months after the second dose, boosts immunity to the deadly virus.
“The group expects Sinovac to provide immediate booster shots, especially for vulnerable and high-risk populations, to maintain protection against viruses, especially against newer variants,” Pharmamaniaga said. paddy field.
The group also has Sinovac Biotech to promote the export of vaccines to countries facing challenges to ensure adequate supply, including Indonesia, the Philippines, Cambodia, Thailand and some African countries. It was revealed that he was in discussions with the company.
“Pharmaniaga’s positive plans have enabled the group to take advantage of these appropriate opportunities,” he said.
A group of high-tech factories under Pharmaniaga LifeScience Sdn Bhd recently received approval from the National Drug Regulatory Agency (NPRA) for the production of two filled and finished Sinovac COVID-19 vaccine doses / vials. As a result, the plant’s capacity will increase from 2 million by August 2021 and 4 million inoculations per month.